Arpraziquantel

Arpraziquantel ((R)-praziquantel) is the eutomer (the biologically active enantiomer) of praziquantel, and is a medication which is currently under investigation for the treatment of schistosomiasis in young children since it has less side effects than the usual racemic mixture formulation of praziquantel.^[1]

Arpraziquantel

Clinical data
Other names	(R)-Praziquantel
Drug class	Anthelmintic
ATC code	P02BA03 (WHO)
Identifiers
CAS Number	57452-98-9
PubChem CID	445900
DrugBank	DB11749
ChemSpider	393394
UNII	WF15T5925V
KEGG	D12741
ChEMBL	ChEMBL1235551
PDB ligand	PZQ (PDBe, RCSB PDB)
CompTox Dashboard (EPA)	DTXSID80904739
Chemical and physical data
Formula	C19H24N2O2
Molar mass	312.413 g·mol−1
3D model (JSmol)	Interactive image
SMILES [H][C@@]12CN(CC(=O)N1CCC1=CC=CC=C21)C(=O)C1CCCCC1
InChI InChI=1S/C19H24N2O2/c22-18-13-20(19(23)15-7-2-1-3-8-15)12-17-16-9-5-4-6-14(16)10-11-21(17)18/h4-6,9,15,17H,1-3,7-8,10-13H2/t17-/m0/s1 Key:FSVJFNAIGNNGKK-KRWDZBQOSA-N

Society and culture

Legal status

In December 2023, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency adopted a positive opinion in accordance with Article 58 of Regulation (EC) No 726/20041 for the medicinal product arpraziquantel, intended for the treatment of schistosomiasis in young children.^[1] The applicant for this medicinal product is Merck Europe B.V.^[1] It is intended exclusively for markets outside the European Union.^[1]

Names

Arpraziquantel is the International nonproprietary name.^[2]